Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Interest & Investment Income (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Interest & Investment Income for 11 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 47.15% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.6 million through Dec 2025, down 42.07% year-over-year, with the annual reading at $10.6 million for FY2025, 42.07% down from the prior year.
  • Interest & Investment Income hit $2.1 million in Q4 2025 for Voyager Therapeutics, down from $2.4 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $4.9 million in Q2 2024 to a low of -$643000.0 in Q4 2021.
  • Historically, Interest & Investment Income has averaged $2.1 million across 5 years, with a median of $2.2 million in 2025.
  • Biggest five-year swings in Interest & Investment Income: tumbled 893.83% in 2021 and later surged 5912.9% in 2023.
  • Year by year, Interest & Investment Income stood at -$643000.0 in 2021, then soared by 251.79% to $976000.0 in 2022, then surged by 223.16% to $3.2 million in 2023, then rose by 26.63% to $4.0 million in 2024, then crashed by 47.15% to $2.1 million in 2025.
  • Business Quant data shows Interest & Investment Income for VYGR at $2.1 million in Q4 2025, $2.4 million in Q3 2025, and $2.8 million in Q2 2025.